Clinical Trials Logo

Papillary Renal Cell Carcinoma clinical trials

View clinical trials related to Papillary Renal Cell Carcinoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04603365 Withdrawn - Clinical trials for Metastatic Renal Cell Carcinoma

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

Start date: October 18, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial investigates how well pamiparib and temozolomide work in treating patients with hereditary leiomyomatosis and renal cell (kidney) cancer. Poly adenosine diphosphate-ribose polymerase (PARPs) are proteins that help repair DNA mutations. PARP inhibitors, such as pamiparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pamiparib and temozolomide may help treat patients with hereditary leiomyomatosis and renal cell cancer.